TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Definium Therapeutics reported that its investigational orally disintegrating LSD formulation, DT120, met the primary endpoints in phase III trials for generalized anxiety disorder and major depressive disorder. The company reported symptom improvements versus placebo, but the available report does not provide full trial publications or establish whether regulators will approve the drug.
Definium Therapeutics said its investigational orally disintegrating tablet of lysergide, or LSD, met the primary endpoints in two phase III trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reported placebo-adjusted symptom improvements lasting through the trials’ 12-week assessment periods; the findings do not mean DT120 is approved or available as a treatment.
In the 214-participant Voyage trial for GAD, patients received one supervised 100-microgram dose of DT120. Their average Hamilton Anxiety Rating Scale score improved by 11.6 points from baseline at week 12. The reported difference from placebo at that point was 5.4 points, with a P value below 0.0001. The trial also found a statistically significant improvement by week one, when the change from baseline was 11.9 points and the difference from placebo was 7.7 points.
In the 149-participant Emerge trial for MDD, DT120 produced an 8.1-point placebo-adjusted improvement on the Montgomery-Åsberg Depression Rating Scale at week six. The reported placebo-adjusted difference was 7.3 points at week 12; both results had P values below 0.0001. The company also reported greater response and remission rates in the DT120 groups than in the placebo groups at the stated assessment points.
Both studies were presented at the Neuroscience Education Institute Fall Congress in Colorado Springs, Colorado. Definium chief medical officer Dan Karlin told MedPage Today that the results offer hope for a new option for people who have had symptoms for years. These are sponsor-reported trial results; the source report does not provide a peer-reviewed paper or complete data tables.
A Different Dosing Model for Two Disorders
The findings could matter because DT120 was given in a single supervised session, rather than as a daily medication in the trial designs described. That approach may appeal to patients and clinicians seeking alternatives, but it also requires a dedicated treatment day and trained clinical personnel. The trial reports describe average symptom-score changes, not a guarantee that an individual patient will improve.
For GAD, the company reported a 12-week response rate of 43% with DT120 versus 16% with placebo, defining response as at least a 50% reduction in HAM-A score. For MDD, the week-six response rate was 35% versus 7%, using a 50% reduction in MADRS score. Those measures help show how many participants crossed defined improvement thresholds, but they do not by themselves establish how DT120 compares with existing treatments or performs in routine clinical care.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Garmin Venu 3S GPS Smartwatch with AMOLED Display, Soft Gold and French Gray Silicone Band
As an affiliate, we earn on qualifying purchases.
What the Two Trials Tested
Voyage enrolled people with substantial GAD symptoms at baseline: the mean HAM-A score was 27.9, and participants had to score at least 20 to enter. Their average age was 42; 64% were women. More than one-third had tried at least two prior GAD medications. DT120 was administered during one supervised session, with an average 6.4 hours to discharge clearance and 90% cleared by hour eight, according to the report.
Emerge enrolled participants with active depressive episodes lasting from eight weeks to 24 months. Their mean baseline MADRS score was 34.5, and 53% had previously received at least two antidepressants. Average discharge-clearance time after dosing was 5.8 hours, and all participants met discharge criteria by hour eight. These participant and session details are relevant to interpreting the results: the studies examined selected patients under supervised conditions, not unsupervised use.
“Seeing a clinically meaningful improvement in patients with this level and duration of disease gives us hope that DT120 could offer a new treatment option for people who have been suffering for years and are still in need of better outcomes.”
— Dan Karlin, Definium Therapeutics chief medical officer, speaking to MedPage Today
Approval and Longer-Term Evidence
The reported results do not establish that DT120 is approved, safe for broad use, or more effective than current treatments. The source account does not give full protocols, detailed statistical analyses, or complete adverse-event tables, and the studies’ results have not been presented here as peer-reviewed publications. Further information is needed to assess the size and durability of benefit, the role of placebo effects, and how the findings hold up across different patient groups.
The company reported no serious adverse events, suicidal behavior, or self-injurious behavior in either study. In Voyage, reported side effects were described as mild to moderate; common events included illusion, nausea, and euphoric mood on dosing day, with headache more common afterward. One participant discontinued because of a treatment-emergent adverse event. In Emerge, the company said 99% of reported adverse events were mild to moderate and no participants discontinued because of adverse events. These summaries do not answer every question about uncommon or longer-term risks.
Regulatory Steps and Full Trial Data
The next key developments are release of fuller trial results and any announcement by Definium about regulatory filings. The report does not state whether the company has submitted applications to regulators, when it might do so, or what additional studies or reviews may be required. Until those details emerge, the phase III findings remain clinical-trial results for an investigational drug, not a change in available treatment options.
Any future regulatory review will need to consider the full efficacy and safety evidence, including the supervised dosing requirements and follow-up beyond the 12-week periods described. Patients should not interpret these trial announcements as a reason to change prescribed care; treatment decisions should be discussed with a qualified health professional.
Key Questions
What is DT120?
DT120 is an investigational orally disintegrating tablet formulation of lysergide, also known as LSD. In the trials described, it was administered as a single dose during a supervised session.
What did the phase III trials find?
Definium reported that DT120 met the primary endpoints in Voyage for GAD and Emerge for MDD. The company reported placebo-adjusted improvements on anxiety and depression symptom scales, including outcomes measured at weeks six or 12.
Is DT120 approved for anxiety or depression?
The source report does not say that DT120 has regulatory approval. It describes an investigational drug and trial results; approval status and any filing plans remain unclear from the information available.
What side effects were reported?
The company said common events included illusion, nausea, and euphoric mood around dosing day, and headache afterward. It characterized most reported events as mild to moderate, but fuller safety data are needed to evaluate risks beyond the study summaries.
Source: medpagetoday.com
